Secretory leukocyte protease inhibitor and elafin/trappin-2: Versatile mucosal antimicrobials and regulators of immunity

American Journal of Respiratory Cell and Molecular Biology

Volumn 42, Issue 6, 2010, Pages 635-643

  Sallenave, Jean Michel ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

Author keywords

Elafin; Immunity; Inflammation; Lung; Secretory lekocyte protease inhibitor

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; BACTERIAL VECTOR; ELAFIN; INTERLEUKIN 1; LEUKOCYTE ELASTASE; LIPOSOME; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; WHEY ACIDIC PROTEIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; CATABOLISM; CELLULAR DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; EMPHYSEMA; ENZYME INHIBITION; EPITHELIUM CELL; FARMER LUNG; GENE TARGETING; GENETIC POLYMORPHISM; HOMEOSTASIS; HOST; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; LACTOCOCCUS LACTIS; LUNG DISEASE; LUNG LAVAGE; NONHUMAN; PATIENT SELECTION; REVIEW; SUPPLEMENTATION; TISSUE DISTRIBUTION; TISSUE REPAIR; ANIMAL; BACTERIAL PNEUMONIA; DRUG EFFECT; GENE THERAPY; GENETICS; HISTORY; IMMUNOLOGY; MICROBIOLOGY; MUCOSAL IMMUNITY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ELAFIN; GENE THERAPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; PNEUMONIA, BACTERIAL; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SIGNAL TRANSDUCTION;

EID: 77953251177     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0095RT     Document Type: Review

References (153)

1. Suzuki T, Chow CW, Downey GP. Role of innate immune cells and their products in lung immunopathology. Int J Biochem Cell Biol 2008;40:1348-1361.
2. Pham CT. Neutrophil serine proteases fine-tune the inflammatory response. Int J Biochem Cell Biol 2008;40:1317-1333.
3. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008;40:1334-1347.
4. Veillard F, Lecaille F, Lalmanach G. Lung cysteine cathepsins: intruders or unorthodox contributorsthe kallikrein-kinin system? Int J Biochem Cell Biol 2008;40:1079-1094.
5. Owen CA. Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. Int J Biochem Cell Biol 2008;40:1246-1272.
6. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol 2004;172:7791-7803. (Pubitemid 38747647)
7. Sallenave JM. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 2000; 1:87-92.
8. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994;11:733-741.
9. Fritz H. Human mucus proteinase inhibitor (human MPI), Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol Chem Hoppe Seyler 1988; 369:79-82.
10. Eisenberg SP, Hale KK, Heimdal P, Thompson RC. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 1990;265:7976-7981. (Pubitemid 20158969)
11. Casslén B, Rosengren M, Ohlsson K. Localization and quantitation of a low molecular weight proteinase inhibitor, antileukoprotease, in the human uterus. Hoppe Seylers Z Physiol Chem 1981;362:953-961. (Pubitemid 11009526)
12. Heinzel R, Appelhans H, Gassen G, Seemüller U, Machleidt W, Fritz H, Steffens G. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur J Biochem 1986;160:61-67. (Pubitemid 17177451)
13. Seemüller U, Arnhold M, Fritz H, Wiedenmann K, Machleidt W, Heinzel R, Appelhans H, Gassen HG, Lottspeich F. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett 1986;199:43-48.
14. Hochstrasser K, Albrecht GJ, Schönberger OL, Rasche B, Lempart K. An elastase-specific inhibitor from human bronchial mucus: isolation and characterization. Hoppe Seylers Z Physiol Chem 1981;362:1369-1375. (Pubitemid 12167425)
15. Kramps JA, Klasen EC. Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion. Exp Lung Res 1985;9:151-165.
16. Wiedow O, Schröder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem 1990;265:14791-14795. (Pubitemid 20296164)
17. Sallenave JM, Ryle AP. Purification and characterization of elastase-specific inhibitor: sequence homology with mucus proteinase inhibitor. Biol Chem Hoppe Seyler 1991;372:13-21.
18. Sallenave JM, Marsden MD, Ryle AP. Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions: evidence of sequence homology and immunological cross-reactivity. Biol Chem Hoppe Seyler 1992;373:27-33.
19. Saheki T, Ito F, Hagiwara H, Saito Y, Kuroki J, Tachibana S, Hirose S. Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment. Biochem Biophys Res Commun 1992;185:240-245.
20. Molhuizen HO, Alkemade HA, Zeeuwen PL, de Jongh GJ, Wieringa B, Schalkwijk J. SKALP/elafin: an elastase inhibitor from cultured human keratinocytes: purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem 1993;268:12028-12032. (Pubitemid 23168166)
21. Sallenave JM, Silva A. Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am J Respir Cell Mol Biol 1993;8:439-445.
22. Jiménez-Vega F, Vargas-Albores F. A secretory leukocyte proteinase inhibitor (SLPI)-like protein from Litopenaeus vannamei haemocytes. Fish Shellfish Immunol 2007;23:1119-1126. (Pubitemid 47376919)
23. Brown TI, Mistry R, Gray R, Imrie M, Collie DD, Sallenave JM. Characterization of the ovine ortholog of secretory leukoprotease inhibitor. Mamm Genome 2005;16:621-630. (Pubitemid 41355925)
24. Brown TI, Mistry R, Collie DD, Tate S, Sallenave JM. Trappin ovine molecule (TOM), the ovine ortholog of elafin, is an acute phase reactant in the lung. Physiol Genomics 2004;19:11-21. (Pubitemid 40039909)
25. Helmig R, Uldbjerg N, Ohlsson K. Secretory leukocyte protease inhibitor in the cervical mucus and in the fetal membranes. Eur J Obstet Gynecol Reprod Biol. 1995;59:95-101.
26. Pfundt R, van Ruissen F, van Vlijmen-Willems IM, Alkemade HA, Zeeuwen PL, Jap PH, Dijkman H, Fransen J, Croes H, van Erp PE, et al. Constitutive and inducible expression of SKALP/elafin provides antielastase defense in human epithelia. J Clin Invest 1996;98:1389-1399.
27. Lundwall A, Ulvsback M. The gene of the protease inhibitor SKALP/ elafin is a member of the REST gene family. Biochem Biophys Res Commun 1996;221:323-327. (Pubitemid 26136470)
28. Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun 2005;333:383-389. (Pubitemid 40848302)
29. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002;368:233-242. (Pubitemid 35463426)
30. Francart C, Dauchez M, Alix AJ, Lippens GJ. Solution structure of R-elafin, a specific inhibitor of elastase. Mol Biol 1997;268:666-677.
31. Nara K, Ito S, Ito T, Suzuki Y, Ghoneim MA, Tachibana S, Hirose S. Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". J Biochem. 1994;115:441-448.
32. Tremblay GM, Sallenave JM, Israél-Assayag E, Cormier Y, Gauldie J. Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am J Respir Crit Care Med 1996;154: 1092-1098.
33. Guyot N, Zani ML, Maurel MC, Dallet-Choisy S, Moreau T. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 2005;44:15610-15618.
34. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci 2006;110:21-35.
35. Jacoby AS, Melrose J, Robinson BG, Hyland VJ, Ghosh P. Secretory leucocyte proteinase inhibitor is produced by human articular cartilage chondrocytes and intervertebral disc fibrochondrocytes. Eur J Biochem 1993;218:951-957.
36. Ohlsson S, Tufvesson B, Polling A, Ohlsson K. Distribution of the secretory leucocyte proteinase inhibitor in human articular cartilage. Biol Chem 1997;378:1055-1058.
37. Jaovisidha K, Etim A, Yamakawa K, Masuda I, Gohr CM, Wakim BT, Boonapatcharoen N, Ninomiya J, Rosenthal AK. The serine protease inhibitor trappin-2 is present in cartilage and synovial fluid in osteoarthritis. J Rheumatol 2006;33:318-325.
38. Reid PT, Marsden ME, Cunningham GA, Haslett C, Sallenave JM. Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett 1999;457:33-37.
39. Abbinante-Nissen JM, Simpson LG, Leikauf GD. Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1993;265:L286-L292.
40. Maruyama M, Hay JG, Yoshimura K, Chu CS, Crystal RG. Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. J Clin Invest 1994;94: 368-375.
41. Abbinante-Nissen JM, Simpson LG, Leikauf GD. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1995;268:L601-L606.
42. Pfundt R, Wingens M, Bergers M, Zweers M, Frenken M, Schalkwijk J. TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch Dermatol Res 2000;292:180-187.
43. Pfundt R, van Vlijmen-Willems I, Bergers M, Wingens M, Cloin W, Schalkwijk J. In situ demonstration of phosphorylated c-jun and p38 MAP kinase in epidermal keratinocytes following ultraviolet B irradiation of human skin. J Pathol 2001;193:248-255.
44. Bingle L, Tetley TD, Bingle CD. Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. Am J Respir Cell Mol Biol 2001;25:84-91.
45. Sørensen OE, Thapa DR, Roupé KM, Valore EV, Sjöbring U, Roberts AA, Schmidtchen A, Ganz T. Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J Clin Invest 2006;116:1878-1885.
46. Velarde MC, Parisek SI, Eason RR, Simmen FA, Simmen RC. The secretory leukocyte protease inhibitor gene is a target of epidermal growth factor receptor action in endometrial epithelial cells. J Endocrinol 2005;184:141-151.
47. King AE, Morgan K, Sallenave JM, Kelly RW. Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochem Biophys Res Commun 2003;310:594-599.
48. King AE, Critchley HO, Sallenave JM, Kelly RW. Elafin in human endometrium: an antiprotease and antimicrobial molecule expressed during menstruation. J Clin Endocrinol Metab 2003;88:4426-4431.
49. King AE, Kelly RW, Sallenave JM, Bocking AD, Challis JR. Innate immune defences in the human uterus during pregnancy. Placenta 2007;28:1099-1106.
50. van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J, Hiemstra PS. Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol 2000;278:L51-L58.
51. Jin F, Nathan CF, Radzioch D, Ding A. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun 1998;66:2447-2452.
52. Sano C, Shimizu T, Tomioka H. Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-kappaB activation of lipopolysaccharide-stimulated macrophages. Cytokine 2003;21:38-42.
53. Jaumann F, Elssner A, Mazur G, Dobmann S, Vogelmeier C; Munich Lung Transplant Group. Transforming growth factor-beta1 is a potent inhibitor of secretory leukoprotease inhibitor expression in a bronchial epithelial cell line. Eur Respir J 2000;15:1052-1057.
54. Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, McElvaney NG, Cathepsin B. L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001;276:33345-33352.
55. Rao NV, Marshall BC, Gray BH, Hoidal JR. Interaction of secretory leukocyte protease inhibitor with proteinase-3. Am J Respir Cell Mol Biol 1993;8:612-616.
56. Guyot N, Butler MW, McNally P, Weldon S, Greene CM, Levine RL, O'Neill SJ, Taggart CC, McElvaney NG. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008;283: 32377-32385.
57. Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003;544:129-132.
58. Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004;72:3684-3687.
59. Dulon S, Candé C, Bunnett NW, Hollenberg MD, Chignard M, Pidard D. Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. Am J Respir Cell Mol Biol 2003;28:339-346.
60. Suzuki T, Moraes TJ, Vachon E, Ginzberg HH, Huang TT, Matthay MA, Hollenberg MD, Marshall J, McCulloch CA, Abreu MT, et al. Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells. Am J Respir Cell Mol Biol 2005;33: 231-247.
61. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 2004;172: 4535-4544.
62. Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 2006;281:34730-34735.
63. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB. O'Neill SJ, McElvaney NG. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005;202:1659-1668.
64. Ying QL, Simon SR.DNA from bronchial secretions modulates elastase inhibition by alpha(1)-proteinase inhibitor and oxidized secretory leukoprotease inhibitor. Am J Respir Cell Mol Biol 2000;23:506-513.
65. Belorgey D, Bieth JG. DNA binds neutrophil elastase and mucus proteinase inhibitor and impairs their functional activity. FEBS Lett 1995;361:265-268.
66. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002;277:2437-2443.
67. He J, Furmanski P. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 1995;373:721-724.
68. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000;106:439-448.
69. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004;200:1337-1346.
70. Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, Benhamou M, Monteiro RC, Hocini H, Madrid R, Benichou S. The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS ONE 2009;4:e5006.
71. Yu KS, Lee Y, Lim CM, Park EC, Choi J, Lim DS, Chung YH, Koh SS The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells. Int J Cancer 2009Dec 17. [Epub ahead of print]
72. Chua F, Dunsmore SE, Clingen PH, Mutsaers SE, Shapiro SD, Segal AW, Roes J, Laurent GJ. Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis. Am J Pathol 2007;170:65-74.
73. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996;64:4520-4524.
74. Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett 1999; 452:309-313.
75. Meyer-Hoffert U, Wichmann N, Schwichtenberg L, White PC, Wiedow O. Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes. Exp Dermatol 2003; 12:418-425.
76. Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau T. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J 2008;275: 2008-2020.
77. Gomez SA, Argüelles CL, Guerrieri D, Tateosian NL, Amiano NO, Slimovich R, Maffia PC, Abbate E, Musella RM, Garcia VE, et al. Secretory leukocyte protease inhibitor: a secreted pattern recognition receptor for mycobacteria. Am J Respir Crit Care Med 2009;179: 247-253.
78. Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis 1997;3:S64-S69.
79. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-464.
80. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997;90:1141-1149.
81. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, et al. Elevated elafin/trappin- 2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009;23:1669-1677.
82. Simpson AJ, Wallace WA, Marsden ME, Govan JR, Porteous DJ, Haslett C, Sallenave JM. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol 2001;167:1778-1786.
83. McMichael JW, Maxwell AI, Hayashi K, Taylor K, Wallace WA, Govan JR, Dorin JR, Sallenave JM. Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect Immun 2005;73:3609-3617.
84. Bellemare A, Vernoux N, Morisset D, Bourbonnais Y. Human preelafin inhibits a Pseudomonas aeruginosa-secreted peptidase and prevents its proliferation in complex media. Antimicrob Agents Chemother 2008;52:483-490.
85. Rudack C, Sachse F, Albert N, Becker K, von Eiff C. Immunomodulation of nasal epithelial cells by Staphylococcus aureus-derived serine proteases. J Immunol 2009;183:7592-7601.
86. Kida Y, Higashimoto Y, Inoue H, Shimizu T, Kuwano K. A novel secreted protease from Pseudomonas aeruginosa activates NF-kappaB through protease-activated receptors. Cell Microbiol 2008; 10:1491-1504.
87. Fernie-King BA, Seilly DJ, Binks MJ, Sriprakash KS, Lachmann PJ. Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities. Microbes Infect 2007;9:300-307.
88. Wex T, Treiber G, Venerito M, Leodolter A, Peitz U, Kuester D, Hritz I, Krueger S, Roessner A, Malfertheiner P. Helicobacter pylori-induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori-mediated diseases. Biol Chem 2006;387:893-901.
89. Kantyka T, Latendorf T, Wiedow O, Bartels J, Gläser R, Dubin G, Schröder JM, Potempa J, Meyer-Hoffert U. Elafin is specifically inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage. Biol Chem 2009;390:1313-1320.
90. Draper D, Donohoe W, Mortimer L, Heine RP. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis 1998;178:815-819.
91. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008;82:9337-9344.
92. Brown A, Farmer K, MacDonald L, Kalsheker N, Pritchard D, Haslett C, Lamb J, Sallenave JM. House dust mite Der p 1 downregulates defenses of the lung by inactivating elastase inhibitors. Am J Respir Cell Mol Biol 2003;29:381-389.
93. Samsom JN, van der Marel AP, van Berkel LA, van Helvoort JM, Simons-Oosterhuis Y, Jansen W, Greuter M, Nelissen RL, Meeuwisse CM, Nieuwenhuis EE, et al. Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance. J Immunol 2007;179:6588-6595.
94. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, Ding A, Knowles DM, Santini PA, Cerutti A. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol 2007;8:294-303.
95. Roghanian A, Drost EM, MacNee W, Howie SE, Sallenave JM. Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. Am J Respir Crit Care Med 2006; 174:1189-1198.
96. Maffia PC, Zittermann SE, Scimone ML, Tateosian N, Amiano N, Guerrieri D, Lutzky V, Rosso D, Romeo HE, Garcia VE, et al. Neutrophil elastase converts human immature dendritic cells into transforming growth factor-beta1-secreting cells and reduces allostimulatory ability. Am J Pathol 2007;171:928-937.
97. Marischen L, Wesch D, Schröder JM, Wiedow O, Kabelitz D. Human gammadelta T cells produce the protease inhibitor and antimicrobial peptide elafin. Scand J Immunol 2009;70:547-552.
98. Simpson AJ, Cunningham GA, Porteous DJ, Haslett C, Sallenave JM. Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum Gene Ther 2001;12:1395-1406.
99. Sallenave JM, Cunningham GA, James RM, McLachlan G, Haslett C. Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 2003;71:3766-3774.
100. McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am J Respir Cell Mol Biol 2005; 32:443-452.
101. Roghanian A, Williams SE, Sheldrake TA, Brown TI, Oberheim K, Xing Z, Howie SE, Sallenave JM. The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity. Am J Respir Cell Mol Biol 2006;34:634-642.
102. Wilkinson TS, Dhaliwal K, Hamilton TW, Lipka AF, Farrell L, Davidson DJ, Duffin R, Morris AC, Haslett C, Govan JR, et al. Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment. Am J Pathol 2009;174:1338-1346.
103. Guyot N, Zani ML, Berger P, Dallet-Choisy S, Moreau T. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. Biol Chem 2005; 386:391-399.
104. Canny G, Levy O. Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites. Trends Immunol 2008;29:541-547.
105. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003;115:13-23.
106. Oppenheim JJ, Tewary P, de la Rosa G, Yang D. Alarmins initiate host defense. Adv Exp Med Biol 2007;601:185-194.
107. Laurell CB, Eriksson S. The electropheric alpha-globulin pattern of serum in alpha-antitrypsin deficiency. Scand J Clin Invest 1963;15: 132-140.
108. Heresi GA, Stoller JK. Augmentation therapy in alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 2008;8:515-526.
109. Mulgrew AT, Taggart CC, McElvaney NG. Alpha-1-antitrypsin deficiency: current concepts. Eur Respir J 2008;32:783-795.
110. Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008;32:783-795.
111. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:253-268.
112. Boudier C, Bieth JG. Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor. Biochem J 1994;303:61-68.
113. Boudier C, Bieth JG. Mucus proteinase inhibitor: a fast-acting inhibitor of leucocyte elastase. Biochim Biophys Acta 1989;995:36-41.
114. Piccioni PD, Kramps JA, Rudolphus A, Bulgheroni A, Luisetti M. Proteinase/proteinase inhibitor imbalance in sputum sol phases from patients with chronic obstructive pulmonary disease. Suggestions for a key role played by antileukoprotease. Chest 1992;102:1470-1476.
115. Rice WG, Weiss SJ. Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 1990;249:178-181.
116. Birrer P, McElvaney NG, Rüdeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-213.
117. Suter S. The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis. Antibiot Chemother 1989;42:158-168.
118. Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, Belaaouaj A, Levine RL, Taggart CC. Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 2009;183:8148-8156.
119. Luo BL, Niu RC, Feng JT, Hu CP, Xie XY, Ma LJ. Downregulation of secretory leukocyte proteinase inhibitor in chronic obstructive lung disease: the role of TGF-beta/Smads signaling pathways. Arch Med Res 2008;39:388-396.
120. Betsuyaku T, Takeyabu K, Tanino M, Nishimura M. Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema. Eur Respir J 2002;19:1051-1057.
121. Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, Crystal RG. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991;87:482-488.
122. Roghanian A, Sallenave JM. Neutrophil elastase (NE) and NE inhibitors: canonical and noncanonical functions in lung chronic inflammatory diseases (cystic fibrosis and chronic obstructive pulmonary disease). J Aerosol Med Pulm Drug Deliv 2008;21:125-144.
123. Gompertz S, Bayley DL, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
124. Sallenave JM, Donnelly SC, Grant IS, Robertson C, Gauldie J, Haslett C. Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. Eur Respir J 1999;13:1029-1036.
125. Cavarra E, Lucattelli M, Gambelli F, Bartalesi B, Fineschi S, Szarka A, Giannerini F, Martorana PA, Lungarella G. Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress. Am J Physiol Lung Cell Mol Physiol 2001;281:L412-L417.
126. Schmid M, Fellermann K, Fritz P, Wiedow O, Stange EF, Wehkamp J. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007;81:907-915.
127. Rudolphus A, Stolk J, van Twisk C, van Noorden CJ, Dijkman JH, Kramps JA. Detection of extracellular neutrophil elastase in hamster lungs after intratracheal instillation of E. coli lipopolysaccharide using a fluorogenic, elastase-specific, synthetic substrate. Am J Pathol 1992;141:153-160.
128. Vogelmeier C, Gillissen A, Buhl R. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Chest 1996;110:261S-266S.
129. Vogelmeier C, Buhl R, Hoyt RF, Wilson E, Fells GA, Hubbard RC, Schnebli HP, Thompson RC, Crystal RG. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol 1990;69:1843-1848.
130. Birrer P, McElvaney NG, Crystal RG. Intravenous recombinant SLPI augments antineutrophil elastase defense. J Appl Physiol 1992;3: 317-323.
131. Gillissen A, Birrer P, McElvaney NG, Buhl R, Vogelmeier C, Hoyt RF Jr, Hubbard RC, Crystal RG. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol 1993;75:825-832.
132. Stolk J, Dijkman JH, Pauwels EK. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax 1995;50:645-650.
133. McElvaney NG, Nakamura H, Birrer P, Hébert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90:1296-1301.
134. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993;148:1056-1060.
135. Abe T, Kobayashi N, Yoshimura K, Trapnell BC, Kim H, Hubbard RC, Brewer MT, Thompson RC, Crystal RG. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 1991;87:2207-2215.
136. Wang Z, Chen F, Zhai R, Zhang L, Su L, Lin X, Thompson T, Christiani DC. Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS ONE 2009;4:e4380.
137. Tejera P, Wang Z, Zhai R, Su L, Sheu CC, Taylor DM, Chen F, Gong MN, Thompson BT, Christiani DC. Genetic polymorphisms of peptidase inhibitor 3 (elafin) are associated with acute respiratory distress syndrome. Am J Respir Cell Mol Biol 2009;41:696-704.
138. Chowdhury MA, Kuivaniemi H, Romero R, Edwin S, Chaiworapongsa T, Tromp G. Identification of novel functional sequence variants in the gene for peptidase inhibitor 3. BMC Med Genet 2006;7:49.
139. Kuijpers AL, Pfundt R, Zeeuwen PL, Molhuizen HO, Mariman EC, van de Kerkhof PC, Schalkwijk J. SKALP/elafin gene polymorphisms are not associated with pustular forms of psoriasis. Clin Genet 1998;54:96-101.
140. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Pääkkö PK, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252:431-434.
141. Wood AM, Stockley RA. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 2007;74:481-492.
142. Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirier A, Garlington W, Baker D, Song S, Berns KI, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006;17:1177-1186. (Pubitemid 44975135)
143. Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ, Humphries M. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004;15:93-128. (Pubitemid 38147192)
144. Kolb M, Martin G, Medina M, Ask K, Gauldie J. Gene therapy for pulmonary diseases. Chest 2006;130:879-884.
145. Griesenbach U, Alton EW; UK Cystic Fibrosis Gene Therapy Consortium. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009;61: 128-139.
146. Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005;99:119-145.
147. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 2007;81:3170-3180. (Pubitemid 46456626)
148. Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005;5:411-427.
149. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355. (Pubitemid 30656052)
150. Forsythe P, Inman MD, Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. Am J Respir Crit Care Med 2007;175:561-569. (Pubitemid 46438940)
151. Cortes-Perez NG, da Costa Medina LF, Lefèvre F, Langella P, Bermúdez-Humarán LG. Production of biologically active CXC chemokines by Lactococcus lactis: evaluation of its potential as a novel mucosal vaccine adjuvant. Vaccine 2008;26:5778-5783.
152. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005;175:7297-7302.
153. Sallenave JM, Bermudez L, Langella P, Vergnolle N. Recombinant probiotic bacteria for the prevention and treatment of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) 2010; European patent EP10305045.6.